{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:56Z","timestamp":1792194956219,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.3109\/14653249.2011.610303","type":"journal-article","created":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T09:31:23Z","timestamp":1316770283000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor"],"prefix":"10.1016","volume":"14","author":[{"given":"Daniela","family":"Montagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Turin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Montini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Secondino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Schiavetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Caliogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Libri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Maccario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3109\/14653249.2011.610303_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.3109\/14653249.2011.610303_bib0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrc1167","article-title":"Adoptive-cell-transfer therapy for the treatment of patients with cancer","volume":"3","author":"Dudley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.3109\/14653249.2011.610303_bib0015","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1200\/JCO.2006.08.3774","article-title":"Immunotherapy for renal cell cancer","volume":"24","author":"Yang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3109\/14653249.2011.610303_bib0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.3109\/14653249.2011.610303_bib0025","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3109\/14653249.2011.610303_bib0030","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3109\/14653249.2011.610303_bib0035","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","article-title":"Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo","volume":"192","author":"Yee","year":"2000","journal-title":"J Exp Med"},{"key":"10.3109\/14653249.2011.610303_bib0040","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"Mackensen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3109\/14653249.2011.610303_bib0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrc862","article-title":"Telomerase beyond telomeres","volume":"2","author":"Blasco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.3109\/14653249.2011.610303_bib0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.1997.tb01026.x","article-title":"Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging","volume":"160","author":"Weng","year":"1997","journal-title":"Immunol Rev"},{"key":"10.3109\/14653249.2011.610303_bib0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2002-07-2015","article-title":"Telomerase levels control the lifespan of human T lymphocytes","volume":"102","author":"Roth","year":"2003","journal-title":"Blood"},{"key":"10.3109\/14653249.2011.610303_bib0060","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"New Eng J Med"},{"key":"10.3109\/14653249.2011.610303_bib0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.3109\/14653249.2011.610303_bib0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3109\/14653249.2011.610303_bib0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14653240701405428","article-title":"GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia","volume":"9","author":"Turin","year":"2007","journal-title":"Cytotherapy"},{"key":"10.3109\/14653249.2011.610303_bib0080","first-page":"111","article-title":"Induction of differentiation in neoplastic cells","volume":"5","author":"Freshney","year":"1985","journal-title":"Anticancer Res"},{"key":"10.3109\/14653249.2011.610303_bib0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ijc.20081","article-title":"Ex vivo generation of anti-tumor cytotoxic T-cell lines derived from patients and their HLA-identical sibling","volume":"110","author":"Montagna","year":"2004","journal-title":"Int J Cancer"},{"key":"10.3109\/14653249.2011.610303_bib0090","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"key":"10.3109\/14653249.2011.610303_bib0095","first-page":"995","article-title":"Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents","volume":"16","author":"Villa","year":"2000","journal-title":"Int J Oncol"},{"key":"10.3109\/14653249.2011.610303_bib0100","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3324\/haematol.13248","article-title":"Donor\/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA- identical sibling","volume":"93","author":"Lisini","year":"2008","journal-title":"Hematologica"},{"key":"10.3109\/14653249.2011.610303_bib0105","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood.V98.12.3359","article-title":"Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy","volume":"98","author":"Montagna","year":"2001","journal-title":"Blood"},{"key":"10.3109\/14653249.2011.610303_bib0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1521-6926(04)00052-0","article-title":"Innovative approaches of adoptive immune cell therapy in pediatric recipients of hematopoietic stem cell transplantation","volume":"17","author":"Locatelli","year":"2004","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.3109\/14653249.2011.610303_bib0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOH.0b013e32832f57d4","article-title":"Cellular therapy to control tumor progression","volume":"16","author":"Kapp","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"10.3109\/14653249.2011.610303_bib0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.molimm.2004.06.040","article-title":"Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues","volume":"42","author":"Ebert","year":"2005","journal-title":"Mol Immunol"},{"key":"10.3109\/14653249.2011.610303_bib0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-065X.2007.00536.x","article-title":"Integrin modulation and signaling in leukocyte adhesion and migration","volume":"218","author":"Rose","year":"2007","journal-title":"Immunol Rev"},{"key":"10.3109\/14653249.2011.610303_bib0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00062752-199502010-00010","article-title":"The L-selectin adhesion system","volume":"2","author":"Stamenkovic","year":"1995","journal-title":"Curr Opin Hematol"},{"key":"10.3109\/14653249.2011.610303_bib0135","first-page":"408","article-title":"Chemokine, SDF-1\/PBSF, and its receptor, CXC chemokine receptor 4, as a mediator of hematopoiesis","volume":"72","author":"Nagasawa","year":"2000","journal-title":"Int J Hematol"},{"key":"10.3109\/14653249.2011.610303_bib0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/clim.2002.5271","article-title":"Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus","volume":"105","author":"Valenzuela","year":"2002","journal-title":"Clin Immunol"},{"key":"10.3109\/14653249.2011.610303_bib0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nbt0898-743","article-title":"Telomere length dynamics in human lymphocyte subpopulation measured by flow cytometry","volume":"16","author":"Rufer","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.3109\/14653249.2011.610303_bib0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.cji.0000211321.07654.b8","article-title":"Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length","volume":"30","author":"Shen","year":"2007","journal-title":"J Immunother"},{"key":"10.3109\/14653249.2011.610303_bib0155","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.4049\/jimmunol.175.10.7046","article-title":"Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy","volume":"175","author":"Zhou","year":"2005","journal-title":"J Immunol"},{"key":"10.3109\/14653249.2011.610303_bib0160","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","article-title":"Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy","volume":"31","author":"Tran","year":"2008","journal-title":"J Immunother"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912706175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912706175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:15:33Z","timestamp":1761430533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324912706175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1465324912706175"],"URL":"https:\/\/doi.org\/10.3109\/14653249.2011.610303","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3109\/14653249.2011.610303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}